These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17824361)

  • 21. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.
    Passamonti B; Gustinucci D; Giorgi Rossi P; Cesarini E; Bulletti S; Carlani A; Martinelli N; Broccolini M; D'Angelo V; D'Amico MR; Di Dato E; Galeazzi P; Malaspina M; Spita N; Tintori B; Giaimo MD
    J Med Screen; 2017 Sep; 24(3):153-162. PubMed ID: 27614992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of diagnostic indicators of cervical cancer screening among women accessing through volunteer organisations and those via the organised programme in Turin (Piedmont Region, Northern Italy).
    Ferrante G; Castagno R; Rizzolo R; Armaroli P; Caprioglio A; Larato C; Giordano L
    Epidemiol Prev; 2020; 44(5-6 Suppl 1):115-123. PubMed ID: 33415954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of colposcopy and treatment--data from the national survey of Italian organised cervical screening programmes: 2006 activity.
    Volante R; Giubilato P; Ronco G
    Epidemiol Prev; 2009; 33(3 Suppl 2):75-82. PubMed ID: 19776488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The STF Project: Female Tumor Screening].
    Branca M; Rossi E; Cedri S; Migliore G; Midulla C; De Lorio P; Giovagnoli MR; Carraro C; Vecchione A; Bonelli L; Nicolò G; Gustavino C; Ferreri M; Barizzone D; Santi L; Morosini PL
    Pathologica; 2001 Feb; 93(1):20-7. PubMed ID: 11294015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Process performance of cervical screening programmes in Europe.
    Ronco G; van Ballegooijen M; Becker N; Chil A; Fender M; Giubilato P; Kurtinaitis J; Lancucki L; Lynge E; Morais A; O'Reilly M; Sparen P; Suteu O; Rebolj M; Veerus P; Zakelj MP; Anttila A
    Eur J Cancer; 2009 Oct; 45(15):2659-70. PubMed ID: 19713100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
    Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
    [No Abstract]   [Full Text] [Related]  

  • 28. [Cervical cancer screening with primary HPV-DNA test in the Local Health Authority 2 of Savona (Liguria Region, Northern Italy): a population-based study].
    Depetrini E; Bonelli L; Ardoino S; Cirucca MC; Contin R; De Leonardis D; Errigo V; Lugani A; Franco A; Pastorino A; Carrozzi G; Venturino E
    Epidemiol Prev; 2016; 40(3-4):171-8. PubMed ID: 27436250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
    Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
    BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).
    Carozzi FM; Iossa A; Scalisi A; Sideri M; Andersson KL; Confortini M; Del Mistro A; Maina G; Ronco G; Raggi P; Schiboni ML; Zappa M; Giorgi Rossi P
    Epidemiol Prev; 2015; 39(3 Suppl 1):84-90. PubMed ID: 26405780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammography screening in Italy: 2004 survey and 2005 preliminary data.
    Giorgi D; Giordano L; Ventura L; Frigerio A; Paci E; Zappa M
    Epidemiol Prev; 2007; 31(2-3 Suppl 2):7-20. PubMed ID: 17824359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The development of the referral outcome diagram and an analysis of laboratory cancer detection rates in the English NHS cervical screening programme--is there an optimum level of detection of CIN 1 and CIN 2 lesions?
    Blanks RG
    Cytopathology; 2008 Aug; 19(4):244-53. PubMed ID: 18476989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A first survey of organized cervical cancer screening programs in Italy. GISCi working group on organization and evaluation. Gruppo Italiano Screening Citologico.
    Ronco G; Iossa A; Naldoni C; Pilutti S; Anghinoni E; Zappa M; Dalla Palma P; Ciatto S; Segnan N
    Tumori; 1998; 84(6):624-30. PubMed ID: 10080665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cervical cancer screening in Italy.
    Segnan N; Ronco G; Ciatto S
    Eur J Cancer; 2000 Nov; 36(17):2235-9. PubMed ID: 11072211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
    Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
    JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.